Citations

Mayo Clinic

Showing 10 of 108551 citations.

Characteristics of and risk factors for COVID-19 breakthrough infections in idiopathic inflammatory myopathies: results from the COVAD study
Ravichandran, Naveen , Day, Jessica , Nune, Arvind , Nikiphorou, Elena , Tan, Ai Lyn , Velikova, Tsvetelina , Milchert, Marcin , Parodis, Ioannis , Kuwana, Masataka , Patel, Aarat , Wincup, Chris , Tehozol, Erick Adrian Zamora , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akarawatcharangura , Kibbi, Lina El , Vaidya, Binit , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Chinoy, Hector , Gupta, Latika, Group, COVAD Study, Ranjan, Rajiv , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , M, Manesh Manoj, Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Gaur, Prithvi Sanjeevkumar , Mamadapur, Mahabaleshwar , Ghodke, Akanksha, Kadam, Esha , Fazal, Zoha Zahid , Kardeş, Sinan , Yıldırım, Reşit, Maurier, F. , Meyer, Alain, Atzeni, Fabiola , Bocci, Elena Bartoloni, Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Grignaschi, Silvia, Giollo, Alessandro, Lini, Daniele , Alluno, Alessia, Loarce‐Martos, Jesus , Aránega, Raquel, Nakashima, Ran , Sato, Shinji , Kaneko, Yuko , Gono, Takahisa, Tomaras, Stylianos , Aharonov, Mr Or, Nagy‐Vincze, Melinda , Schrieber, Karen, bouchti, Pr Imane El, Baba, Zineb, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Olaosebikan, Hakeem , Becky, A, Koussougbo, Ouma Devi , Palalane, Elisa, Limaye, Vidya, Hudson, Marie , Landon‐Cardinal, Océane, Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Doskaliuk, Bohdana , Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Harifi, Ghita, Fuentes-Silva, Yurilís , Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Argueta, Sandra, Quijivix, Daniel, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, M, Roberto Morales Idania Escalante, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Agarwal, Vikas , Giollo, Alessandro , Gupta, Latika , Naveen, R , Day, Jessica , Nune, Arvind , Tan, Ai Lyn , Ziade, Nelly , Milchert, Marcin , Parodis, Ioannis , Gracia-Ramos, Abraham Edgar , Kuwana, Masataka , Knitza, Johannes , Pauling, John D , Wincup, Chris , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Lilleker, James B , Gheita, Tamer , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Agarwal, Vikas , Velikova, Tsvetelina , Zamora Tehozol, Erick Adrian , Dey, Dzifa , Caballero-Uribe, Carlo Vinicio , De Angelis, Rossella , Hoff, Leonardo Santos , Sen, Parikshit , Joshi, Mrudula , Saha, Sreoshy , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Jagtap, Kshitij , Gracia‐Ramos, Abraham Edgar , Cavagna, Lorenzo , Chen, Yi‐Ming , Makol, Ashima , Agarwal, Vishwesh , Pauling, John D , Barman, Bhupen , Rojas Serrano, Jorge , Torre, Ignacio García‐De La , Colunga-Pedraza, I. J. , Goo, Phonpen Akawatcharangura , Shumnalieva, Russka , Halabi, Hussein , Gheita, Tamer A. , Chatterjee, Tulika , Distler, Oliver , Saavedra, Miguel A , Aggarwal, Rohit , Group, COVAD Study, Singh, Yogesh Preet , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Pande, Arun K. , Chandwar, Kunal , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Giannini, Margherita , Campagne, Julien , Meyer, Alain , Papa, Nicoletta Del , Sambataro, Gianluca , Govoni, Marcello , Parisi, Simone , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Sainaghi, Pier Paolo , Venerito, Vincenzo , Andréoli, Laura , Iannone, Florenzo , Fornaro, Marco , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Prieto‐González, Sergio , Yoshida, Akira , Kimura, Naoki, Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Griger, Zoltán , Hmamouchi, Ihsane , Emorinken, Airenakho , Langguth, Daman , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Landon‐Cardinal, Océane , Arbeláez-Cortés, Álvaro , Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , So, Ho , Ugarte‐Gil, Manuel F. , Fathi, Hanan Mohamed , Mohammed, Reem Hamdy A , Harifi, Ghita , Salinas, Rodrigo Nicolás Garcia

Rheumatology | March 2, 2024 | Volume: 64 | Issue: 2 | Pages: 597-606

10.1093/rheumatology/keae128 | PMID 38430474 Get It

Abstract Objectives The objective of this study was to explore the prevalence, characteristics and risk factors of COVID-19 breakthrough infections (BIs) in idiopathic inflammatory myopathies (IIMs) using data from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Methods A validated patient self-reporting e-survey was circulated by the COVAD study group to collect data on COVID-19 infection and vaccination in 2022. BIs were defined as COVID-19 occurring ≥14 days after two vaccine doses. We compared BI characteristics and severity among patients with IIMs, patients with other autoimmune rheumatic and non-rheumatic diseases (AIRD, nrAID), and healthy controls (HCs). Multivariable Cox regression models were used to assess the risk factors for BI, severe BI ,and hospitalizations among patients with IIMs. Results Among the 9449 included responses, BIs occurred in 1447 respondents (15.3%). The median age was 44 years [interquartile range (IQR) 21], 77.4% were female, and 182 BIs (12.9%) occurred among the 1406 patients with IIMs. Multivariable Cox regression among the data for patients with IIMs showed increasing age to be a protective factor for BIs [hazard ratio (HR) = 0.98, 95% CI = 0.97–0.99], and HCQ and SSZ use were risk factors (HR = 1.81, 95% CI = 1.24–2.64, and HR = 3.79, 95% CI = 1.69–8.42, respectively). Glucocorticoid use was a risk factor for a severe BI (HR = 3.61, 95% CI = 1.09–11.8). Non-white ethnicity (HR = 2.61, 95% CI = 1.03–6.59) was a risk factor for hospitalization. Compared with other groups, patients with IIMs required more supplemental oxygen therapy (IIMs = 6.0% vs AIRDs = 1.8%, nrAIDs = 2.2% and HCs = 0.9%), intensive care unit admission (IIMs = 2.2% vs AIRDs = 0.6%, nrAIDs and HCs = 0%), advanced treatment with antiviral or monoclonal antibodies (IIMs = 34.1% vs AIRDs = 25.8%, nrAIDs = 14.6% and HCs = 12.8%) and had more hospitalization (IIMs = 7.7% vs AIRDs = 4.6%, nrAIDs = 1.1% and HCs = 1.5%). Conclusion Patients with IIMs are susceptible to severe COVID-19 BIs. Age and immunosuppressive treatments were related to the risk of BIs.
Sexual Medicine Society of North America (SMSNA)/American Urological Association (AUA) telemedicine and men’s health white paper
Khera, Mohit , Bernie, Helen L. , Carrier, Serge , Faraday, Martha M., Köhler, Tobias , Jenkins, Lawrence C. , Watter, Daniel N., Mulhall, John P. , Rubin, Rachel , Spitz, Aaron, Yafi, Faysal A. , Sadeghi‐Nejad, Hossein , Broderick, Gregory, Jenkins, Lawrence , Broderick, Gregory A. , Raheem, Omer A. , Ramasamy, Ranjith

The Journal of Sexual Medicine | March 2, 2024 | Volume: 21 | Issue: 4 | Pages: 318-332

10.1093/jsxmed/qdad151 | PMID 38430132 Get It

Abstract Purpose The purpose of this white paper is to educate health care professionals about the evolution of telemedicine (TM) and to propose a hybrid model that leverages the strengths of traditional in-person medicine as well as virtual medicine while maximizing the safety and quality of men’s sexual health care. Literature Search Strategy A literature search focused on the use of TM in urology and men’s health was performed through PubMed/MEDLINE, Embase, and Web of Science (January 1, 2012–April 26, 2022). Keywords included all known permutations of the terminology used to refer to virtual health, care as well as the terminology used to refer to urologic diseases, issues specific to men’s health, and men’s sexual health concerns. Publications that emerged after the literature search that met this criterion also were incorporated. Opinion pieces, letters to the editor, meeting abstracts, and conference proceedings were excluded. Additional resources were retrieved, such as governmental technical reports, legislative updates and reviews, and blogs. This search strategy yielded 1684 records across databases after removal of duplicates. Abstracts from the retrieved records were reviewed for relevance. Relevant publications were defined as those that reported data on any aspect of TM use specific to urology, men’s health, and/or men’s sexual health. If relevance was unclear from the abstract, then the full text of the article was retrieved for a more detailed review. In addition, the published evidence-based practice guidelines relevant to care for erectile dysfunction, Peyronie’s disease, ejaculatory dysfunction, and hypogonadism were retrieved. The most common reasons for article exclusions were a focus on TM use in disciplines other than urology and the absence of data (ie, opinion pieces). After exclusions, a total of 91 publications remained and constituted the evidence base for this paper.
Smouldering multiple myeloma: To seek or not to seek? To treat or not to treat. That is the question
Gatt, Moshe E. , Vaxman, Iuliana , Gatt, Moshe E , Vaxman, Iuliana

British Journal of Haematology | March 2, 2024 | Volume: 204 | Issue: 4 | Pages: 1141-1142

10.1111/bjh.19369 | PMID 38429858 Get It

In this issue, the British Society for Haematology presents guidelines for the diagnosis and management of patients with smouldering multiple myeloma (SMM). The authors provide a practical, evidence‐based approach to managing these patients. Key questions remain yet unsolved.Commentary on: Hughes et al. Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper. Br J Haematol 2024;204:1193‐1206.
Epidemiology, Timing, and Secondary Prophylaxis of Recurrent Nocardiosis
Yetmar, Zachary A. , Khodadadi, Ryan B. , Chesdachai, Supavit , McHugh, Jack , Wengenack, Nancy L. , Bosch, Wendelyn , Seville, Maria Teresa , Beam, Elena , McHugh, Jack , Challener, Douglas , Wengenack, Nancy L , Bosch, Wendelyn , Seville, Maria Teresa , Beam, Elena , Yetmar, Zachary A , Khodadadi, Ryan B , Chesdachai, Supavit , Challener, Douglas W.

Open Forum Infectious Diseases | March 1, 2024 | Volume: 11 | Issue: 4 | Pages: No page available

10.1093/ofid/ofae122 | PMID 38560606 Get It

Abstract Background Nocardia tends to cause infection in immunocompromised patients or those with chronic pulmonary disease. Nocardia is known to recur, prompting the practice of secondary prophylaxis in patients perceived at high risk. However, few data exist regarding the epidemiology of recurrent nocardiosis or the effectiveness of secondary prophylaxis. Methods We performed a multicenter, retrospective cohort study of adults diagnosed with nocardiosis from November 2011 to April 2022, including patients who completed primary treatment and had at least 30 days of posttreatment follow-up. Propensity score matching was used to analyze the effect of secondary prophylaxis on Nocardia recurrence. Results Fifteen of 303 (5.0%) patients developed recurrent nocardiosis after primary treatment. Most recurrences were diagnosed either within 60 days (N = 6/15, 40.0%) or between 2 to 3 years (N = 4/15, 26.7%). Patients with primary disseminated infection tended to recur within 1 year, whereas later recurrences were often nondisseminated pulmonary infection. Seventy-eight (25.7%) patients were prescribed secondary prophylaxis, mostly trimethoprim-sulfamethoxazole (N = 67/78). After propensity-matching, secondary prophylaxis was not associated with reduced risk of recurrence (hazard ratio, 0.96; 95% confidence interval, .24–3.83), including in multiple subgroups. Eight (53.3%) patients with recurrent nocardiosis required hospitalization and no patients died from recurrent infection. Conclusions Recurrent nocardiosis tends to occur either within months because of the same Nocardia species or after several years with a new species. Although we did not find evidence for the effectiveness of secondary prophylaxis, the confidence intervals were wide. However, outcomes of recurrent nocardiosis are generally favorable and may not justify long-term antibiotic prophylaxis for this indication alone.
Impact of Early Rejection Treatment on Infection Development in Kidney Transplant Recipients: A Propensity Analysis
Gupta, Simran , Gea‐Banacloche, Juan , Heilman, Raymond L. , Yaman, Reena , Me, Hay Me , Vikram, Holenarasipur R. , Kodali, Lavanya , Yaman, Reena N, Vikram, Holenarasipur R. , Zhang, Nan

Journal of Transplantation | March 1, 2024 | Volume: 2024 | Issue: No issue available | Pages: 1-9

10.1155/2024/6663086 | PMID 38463548 Get It

Introduction. The impact of renal allograft rejection treatment on infection development has not been formally defined in the literature. Methods. We conducted a retrospective cohort study of 185 rejection (case) and 185 nonrejection (control) kidney transplant patients treated at our institution from 2014 to 2020 to understand the impact of rejection on infection development. Propensity scoring was used to match cohorts. We collected data for infections within 6 months of rejection for the cases and 18 months posttransplant for controls. Results. In 370 patients, we identified 466 infections, 297 in the controls, and 169 in the cases. Urinary tract infections (38.9%) and cytomegalovirus viremia (13.7%) were most common. Cumulative incidence of infection between the case and controls was 2.17 (CI 1.54–3.05); p<0.001. There was no difference in overall survival (HR 0.90, CI 0.49–1.66) or graft survival (HR 1.27, CI 0.74–2.20) between the groups. There was a significant difference in overall survival (HR 2.28, CI 1.14–4.55; p=0.019) and graft survival (HR 1.98, CI 1.10–3.56; p=0.023) when patients with infection were compared to those without. Conclusions. As previously understood, rejection treatment is a risk factor for subsequent infection development. Our data have defined this relationship more clearly. This study is unique, however, in that we found that infections, but not rejection, negatively impacted both overall patient survival and allograft survival, likely due to our institution’s robust post-rejection protocols. Clinicians should monitor patients closely for infections in the post-rejection period and have a low threshold to treat these infections while also restarting appropriate prophylaxis.
Digital eye strain and its associated factors among radiology physicians in Pakistan: a cross-sectional survey using logistic regression analysis
Tahir, Muhammad Junaid , Aymen, Ummey, Hassan, Zair , Naz, Nasreen , Rafiq, Nida, Tayyeb, Muhammad , Ullah, Irfan , Alwalid, Osamah , Sohaib Asghar, Muhammad, Abbasher Hussien Mohamed Ahmed, Khabab , Ullah, Irfan , Mehmood, Qasim , Asghar, Muhammad Sohaib , Kumari, Usha , Ahmed, Khabab Abbasher Hussien Mohamed

Annals of Medicine & Surgery | March 1, 2024 | Volume: 86 | Issue: 4 | Pages: 1933-1941

10.1097/ms9.0000000000001882 | PMID 38576948 Get It

Background and aims: Increased use of digital devices in the modern era has led to the development of digital eye strain (DES) or computer vision syndrome in their users. This can result in the development of various ocular and visual symptoms among them. In this study, the authors aimed to view the prevalence of digital eye strain among radiology physicians in Pakistan and their associated risk factors. Materials and methods: A cross-sectional study was conducted to evaluate occupational DES among radiology physicians in Pakistan. The data collection was done using the convenience sampling technique, and the data were analyzed using IBM SPSS for Windows, Version 25.0. Results: Out of the 247 respondents, 33.6% were males and 66.4% were females. 41.7% of them were between 30 and 40 years of age and 51.8% of them were radiology residents. 52.2% of the participants had a refractive error and were using a corrective lens. The majority of the radiologists in our study (84.2%) preferred picture archiving and communication system (PACS) over films and 82.2% of them reported having breaks of less than 15 min. Major symptoms reported by the participants were tired or heavy eyes (69.6%) and headache (69.3%). The proportion of developing DES was higher in females [P=0.001, adjusted odds ratio (aOR)=2.94], radiology residents (P=0.031, aOR=3.29), and working hours of more than 4 h per day (P<0.001, aOR=0.04). Conclusion: With recent advances in the field of radiology in Pakistan, the frequency of developing DES among radiologists is increasing. Being a female, having long working hours, and having noticeable flickers on the digital screens were among the significant factors in developing DES among radiologists.
Brentuximab-induced pneumonitis and organizing pneumonia: a case report with literiture review
Khalil, Omar , Mallah, Shatha M. A., Owda, Fahed , Salim, Hamza , Mallah, Haneen, Azar, Jehad , Salim, Hamza , Mallah, Shatha

Annals of Medicine & Surgery | March 1, 2024 | Volume: 86 | Issue: 5 | Pages: 3029-3035

10.1097/ms9.0000000000001878 | PMID 38694384 Get It

Introduction and importance: Brentuximab vedotin (BV) is an anti-CD30 antibody approved for various cancers, including refractory Hodgkin lymphoma (HL), anaplastic large-cell lymphoma (ALCL) among others. In general, BV has been found to be well-tolerated, with the most frequently reported side effects being peripheral neuropathy and neutropenia. BV-induced pneumonitis is extremely rare. To the best of our knowledge, this is the sixth reported instance of BV-induced lung toxicity. Case presentation: This case presents a female patient in her forties diagnosed with cutaneous T-cell lymphoma undergoing BV treatment. She developed acute hypoxic respiratory failure, ultimately, underwent a diagnostic evaluation including a computed tomography (CT) scan, which showed bilateral airspace consolidations and ground-glass opacities, suggestive of organizing pneumonia and diffuse alveolar damage. Bronchoscopy with bronchoalveolar lavage and transbronchial biopsy ruled out infection, and pulmonary lymphoma and confirmed the diagnosis of BV-induced pneumonitis. The patient had significant clinical improvement after stopping the offending agent, and starting steroids, with optimal clinical recovery at 8 weeks follow-up. Clinical discussion: Drug-related pneumonitis poses a significant concern in the management of cancer patients. Numerous chemotherapeutic agents, such as bleomycin, cyclophosphamide, methotrexate, thalidomide, and others, have been associated with pulmonary-related toxicities. These adverse effects primarily stem from direct toxicity or immunosuppression-related infections. Less commonly, immune-mediated injury may occur. Conclusion: Physicians must have a high index of suspicion for BV-induced pneumonitis, hence, early recognition with subsequent holding of the causative agent, initiation of immunosuppression with steroids, and occasionally steroid-sparing medications, prevent an otherwise fatal outcome.
Evasive Spike Variants Elucidate the Preservation of T Cell Immune Response to the SARS-CoV-2 Omicron Variant
Solanki, Arnav , Cornette, James, Udell, Julia , Vasmatzis, George , Riedel, Marc D. , Vasmatzis, George

IEEE/ACM Transactions on Computational Biology and Bioinformatics | March 1, 2024 | Volume: 21 | Issue: 3 | Pages: 450-460

10.1109/tcbb.2024.3372100 | PMID 38427545 Get It

Keeping an Eye Out for Immunotherapy Toxicity: A Case of Unilateral Ptosis Caused by Ipilimumab/Nivolumab Therapy
Jazieh, Khalid , Kottschade, Lisa A. , Kottschade, Lisa, Dimou, Anastasios

Journal of Immunotherapy and Precision Oncology | March 1, 2024 | Volume: 7 | Issue: 2 | Pages: 126-129

10.36401/jipo-23-44 | PMID 38721405 Get It

ABSTRACT Despite ocular adverse events from immune checkpoint inhibitors being uncommon, they are still important complications to be aware of. We present the case of metastatic melanoma on ipilimumab/nivolumab in a patient who developed immunotherapy complications with delayed diagnosis because the only presenting symptom was unilateral ptosis. We reviewed the literature for relevant and important ocular and neurological complications of immune checkpoint inhibitors.
A small molecule MST1/2 inhibitor accelerates murine liver regeneration with improved survival in models of steatohepatitis
Watkins, Ryan , Gamo, Ana M. , Choi, Seung Hyuk , Kumar, Manoj , Buckarma, EeeLN H. , McCabe, Chantal E. , Tomlinson, Jennifer L. , Pereya, David, Lupše, Blaž , Geravandi, Shirin , Werneburg, Nathan W., Zhu, Siying , Li, Sijia, Yu, Shan , Surakattula, Murali, Baguley, Tyler D., Ardestani, Amin , Roland, Jason, Petrassi, Mike, Rogers, Nikki Lynn, Chatterjee, Arnab K. , Tremblay, Matthew S. , Smoot, Rory L. , Buckarma, EeeLN , McCabe, Chantal , Tomlinson, Jennifer , Wang, Chen , Starlinger, Patrick , Li, Sijia , Ardestani, Amin , Maedler, Kathrin , Joseph, Sean , Rogers, Nikki , Gores, Gregory J. , Chatterjee, Arnab , Shen, Weijun , Smoot, Rory L , Wang, Chen , Starlinger, Patrick , Nguyen-Tran, Vân T. B. , Gores, Gregory J.

PNAS Nexus | March 1, 2024 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/pnasnexus/pgae096 | PMID 38528952 Get It

Abstract Dysfunctional liver regeneration following surgical resection remains a major cause of postoperative mortality and has no therapeutic options. Without targeted therapies, the current treatment paradigm relies on supportive therapy until homeostasis can be achieved. Pharmacologic acceleration of regeneration represents an alternative therapeutic avenue. Therefore, we aimed to generate a small molecule inhibitor that could accelerate liver regeneration with an emphasis on diseased models, which represent a significant portion of patients who require surgical resection and are often not studied. Utilizing a clinically approved small molecule inhibitor as a parent compound, standard medicinal chemistry approaches were utilized to generate a small molecule inhibitor targeting serine/threonine kinase 4/3 (MST1/2) with reduced off-target effects. This compound, mCLC846, was then applied to preclinical models of murine partial hepatectomy, which included models of diet-induced metabolic dysfunction-associated steatohepatitis (MASH). mCLC846 demonstrated on target inhibition of MST1/2 and reduced epidermal growth factor receptor inhibition. The inhibitory effects resulted in restored pancreatic beta-cell function and survival under diabetogenic conditions. Liver-specific cell-line exposure resulted in Yes-associated protein activation. Oral delivery of mCLC846 perioperatively resulted in accelerated murine liver regeneration and improved survival in diet-induced MASH models. Bulk transcriptional analysis of regenerating liver remnants suggested that mCLC846 enhanced the normal regenerative pathways and induced them following liver resection. Overall, pharmacological acceleration of liver regeneration with mCLC846 was feasible, had an acceptable therapeutic index, and provided a survival benefit in models of diet-induced MASH.